IS7718A - Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmar - Google Patents
Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmarInfo
- Publication number
- IS7718A IS7718A IS7718A IS7718A IS7718A IS 7718 A IS7718 A IS 7718A IS 7718 A IS7718 A IS 7718A IS 7718 A IS7718 A IS 7718A IS 7718 A IS7718 A IS 7718A
- Authority
- IS
- Iceland
- Prior art keywords
- thalazone
- substituted piperidine
- dione substituted
- pyrrolidine dione
- inhibits pde4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02017977 | 2002-08-10 | ||
PCT/EP2003/008675 WO2004018457A1 (en) | 2002-08-10 | 2003-08-06 | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
IS7718A true IS7718A (is) | 2005-02-28 |
IS2416B IS2416B (is) | 2008-10-15 |
Family
ID=31896827
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7718A IS2416B (is) | 2002-08-10 | 2005-02-28 | Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmar |
IS7721A IS7721A (is) | 2002-08-10 | 2005-03-01 | Píperidín-pýrídasón og þalasón sem PDE4 hemlar |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7721A IS7721A (is) | 2002-08-10 | 2005-03-01 | Píperidín-pýrídasón og þalasón sem PDE4 hemlar |
Country Status (18)
Country | Link |
---|---|
US (2) | US7220746B2 (is) |
EP (2) | EP1556049A1 (is) |
JP (2) | JP2005538140A (is) |
KR (1) | KR101131684B1 (is) |
CN (1) | CN1671695A (is) |
AT (1) | ATE360627T1 (is) |
AU (2) | AU2003258576B2 (is) |
BR (1) | BR0313330A (is) |
CA (2) | CA2494613C (is) |
DE (1) | DE60313472T2 (is) |
ES (1) | ES2286491T3 (is) |
HR (1) | HRP20050198A2 (is) |
IL (1) | IL166271A (is) |
IS (2) | IS2416B (is) |
MX (1) | MXPA05001354A (is) |
PL (2) | PL214701B1 (is) |
RS (1) | RS51445B (is) |
WO (2) | WO2004018457A1 (is) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK11382003A3 (sk) | 2001-02-15 | 2004-01-08 | Altana Pharma Ag | Piperidino-deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
RS52908B (en) | 2003-03-10 | 2014-02-28 | Takeda Gmbh | NEW PROCEDURE FOR OBTAINING ROFLUMILAST |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
WO2005075437A1 (en) * | 2004-02-04 | 2005-08-18 | Altana Pharma Ag | Pyridazinone derivatives and their use as pde4 inhibitors |
JP4778449B2 (ja) * | 2004-02-04 | 2011-09-21 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pde4インヒビターとしての2−(ピペリジン−4−イル)−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体 |
JP2007536350A (ja) * | 2004-05-10 | 2007-12-13 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肺気腫の予防又は治療のためのロフルミラストの使用 |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
EP1861074B1 (en) | 2005-03-16 | 2013-04-24 | Takeda GmbH | Taste masked dosage form containing roflumilast |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
US8258141B2 (en) | 2006-04-21 | 2012-09-04 | Novartis Ag | Organic compounds |
US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
RU2009120389A (ru) | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Гетероциклические соединения в качестве противовоспалительных агентов |
DK2104535T3 (da) | 2007-01-10 | 2011-04-04 | Irm Llc | Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer |
US8217202B2 (en) * | 2007-04-11 | 2012-07-10 | New Mexico Highlands University | Single carbon precursor synthons |
PL2155721T3 (pl) | 2007-05-07 | 2011-07-29 | Novartis Ag | Związki organiczne |
US8304436B2 (en) * | 2007-05-16 | 2012-11-06 | Nycomed Gmbh | Pyrazolone derivatives as PDE4 inhibitors |
PE20091096A1 (es) | 2007-12-10 | 2009-08-25 | Novartis Ag | Compuestos organicos |
KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
BRPI0915018A2 (pt) | 2008-06-10 | 2015-10-27 | Novartis Ag | compostos orgânicos |
AR074318A1 (es) * | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (es) | 2009-08-12 | 2012-02-29 | Novartis Ag | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. |
CN105078978A (zh) | 2009-08-17 | 2015-11-25 | 因特利凯公司 | 杂环化合物及其用途 |
EP2467383A1 (en) | 2009-08-20 | 2012-06-27 | Novartis AG | Heterocyclic oxime compounds |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
PE20140378A1 (es) | 2011-02-25 | 2014-03-28 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
CN103582644B (zh) | 2011-06-17 | 2016-07-20 | 塔科达有限责任公司 | 酞嗪酮-吡咯并嘧啶羧酰胺衍生物 |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | N−置換ヘテロシクリルカルボキサミド類 |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
CN106458980A (zh) | 2014-04-24 | 2017-02-22 | 诺华股份有限公司 | 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物 |
MX2016013812A (es) | 2014-04-24 | 2017-03-09 | Novartis Ag | Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa. |
CN106458966B (zh) | 2014-04-24 | 2019-05-07 | 诺华股份有限公司 | 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物 |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
MX2017001461A (es) | 2014-07-31 | 2017-05-11 | Novartis Ag | Terapia de combinacion. |
CA3139634A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
CN113105411B (zh) * | 2019-06-28 | 2023-03-17 | 深圳市三启药物开发有限公司 | 腙酰胺类衍生物及药物组合物 |
CN114341132A (zh) | 2019-08-28 | 2022-04-12 | 诺华股份有限公司 | 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06501941A (ja) * | 1990-10-16 | 1994-03-03 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | アリールピリダジノン |
US5716954A (en) * | 1991-10-09 | 1998-02-10 | Syntex U.S.A. Inc. | Benzopyridazinone and pyridopyridazinone compounds |
HUT66969A (en) | 1991-10-09 | 1995-01-30 | Syntex Inc | Benzo- and pyrido-pyridazinone- and pyridazin-thion derivatives, pharmaceutical compositions containing the same and process for the production of thereof |
KR950704228A (ko) | 1992-12-02 | 1995-11-17 | 알렌 제이. 스피겔 | 선택적 포스포디에스테르가수분해효소 iv형(pde_iv) 저해제로서의 카테콜 디에테르(catecol diethers as selective pde_iv inhibitors) |
DE19533975A1 (de) | 1995-09-14 | 1997-03-20 | Merck Patent Gmbh | Arylalkyl-diazinone |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
NZ336573A (en) * | 1997-01-15 | 2000-10-27 | Byk Gulden Lomberg Chem Fab | 4-Phenyl substituted phthalazin-1-one derivatives useful for treating airway disorders |
EP1042319B1 (en) * | 1997-12-15 | 2004-02-04 | ALTANA Pharma AG | Dihydrobenzofurans |
WO1999031071A1 (en) | 1997-12-15 | 1999-06-24 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New phthalazinones |
PT1070056E (pt) | 1998-03-14 | 2004-11-30 | Altana Pharma Ag | Inibidores de pde iii/iv a base de ftalazinona |
AU7654200A (en) | 1999-09-14 | 2001-04-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone derivatives as pd3/4 inhibitors |
ATE374189T1 (de) | 1999-10-25 | 2007-10-15 | Nycomed Gmbh | Phthalazinon-derivate als pde 4 hemmer |
CZ20021457A3 (cs) * | 1999-10-25 | 2002-07-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tetrahydrothiopyranové sloučeniny |
WO2001094319A1 (en) * | 2000-06-05 | 2001-12-13 | Altana Pharma Ag | Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors |
SK11382003A3 (sk) * | 2001-02-15 | 2004-01-08 | Altana Pharma Ag | Piperidino-deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
DE10112864A1 (de) * | 2001-03-16 | 2002-09-19 | Alstom Switzerland Ltd | Verfahren zum Zünden einer thermischen Turbomaschine |
EA200301101A1 (ru) | 2001-04-25 | 2004-04-29 | Алтана Фарма Аг | Производные пиперазина и их применение в качестве ингибиторов pde4 |
PL363312A1 (en) * | 2001-04-25 | 2004-11-15 | Altana Pharma Ag | Novel phthalazinones |
-
2003
- 2003-08-06 AT AT03792257T patent/ATE360627T1/de active
- 2003-08-06 PL PL373645A patent/PL214701B1/pl unknown
- 2003-08-06 RS YUP-2005/0112A patent/RS51445B/en unknown
- 2003-08-06 EP EP03792267A patent/EP1556049A1/en not_active Withdrawn
- 2003-08-06 CA CA2494613A patent/CA2494613C/en not_active Expired - Fee Related
- 2003-08-06 BR BR0313330-3A patent/BR0313330A/pt not_active Application Discontinuation
- 2003-08-06 EP EP03792257A patent/EP1537100B1/en not_active Expired - Lifetime
- 2003-08-06 AU AU2003258576A patent/AU2003258576B2/en not_active Ceased
- 2003-08-06 CN CNA038185202A patent/CN1671695A/zh active Pending
- 2003-08-06 AU AU2003260376A patent/AU2003260376A1/en not_active Abandoned
- 2003-08-06 WO PCT/EP2003/008675 patent/WO2004018457A1/en active IP Right Grant
- 2003-08-06 ES ES03792257T patent/ES2286491T3/es not_active Expired - Lifetime
- 2003-08-06 KR KR1020057001920A patent/KR101131684B1/ko not_active IP Right Cessation
- 2003-08-06 JP JP2004530096A patent/JP2005538140A/ja active Pending
- 2003-08-06 DE DE60313472T patent/DE60313472T2/de not_active Expired - Lifetime
- 2003-08-06 PL PL03372926A patent/PL372926A1/xx not_active Application Discontinuation
- 2003-08-06 US US10/523,412 patent/US7220746B2/en not_active Expired - Fee Related
- 2003-08-06 CA CA002494634A patent/CA2494634A1/en not_active Abandoned
- 2003-08-06 MX MXPA05001354A patent/MXPA05001354A/es active IP Right Grant
- 2003-08-06 JP JP2004530086A patent/JP4555684B2/ja not_active Expired - Fee Related
- 2003-08-06 US US10/523,111 patent/US20060094710A1/en not_active Abandoned
- 2003-08-06 WO PCT/EP2003/008724 patent/WO2004017974A1/en not_active Application Discontinuation
-
2005
- 2005-01-13 IL IL166271A patent/IL166271A/en not_active IP Right Cessation
- 2005-02-28 IS IS7718A patent/IS2416B/is unknown
- 2005-03-01 HR HR20050198A patent/HRP20050198A2/hr not_active Application Discontinuation
- 2005-03-01 IS IS7721A patent/IS7721A/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS7718A (is) | Pýrrólídíndíónútskipt píperídín-þalasón sem PDE4 tálmar | |
HRP20050228A2 (en) | Novel phenanthridines | |
DE60310576D1 (en) | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer | |
ATE471324T1 (de) | Triazolophthalazine | |
EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
EA200300836A1 (ru) | Производные фталазинон-пиперидина в качестве ингибиторов pde4 | |
TW200637853A (en) | Fungicides | |
TW200618800A (en) | Heterocyclic compounds | |
WO2004018449A8 (en) | Piperidine-derivatives as pde4 inhibitors | |
TW200600499A (en) | Novel amido-substituted hydroxy-6-phenylphenanthridines | |
EA200601568A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
ATE413388T1 (de) | Muskarin antagonisten | |
EA201270630A1 (ru) | Гетероциклические сетр ингибиторы | |
EA200801366A1 (ru) | Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина | |
SE0103710D0 (sv) | Compounds | |
NO20064491L (no) | Nye difluomtoksysubstituee hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer | |
DE602004005881D1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
DE602004018811D1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
DE602005005638D1 (de) | 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren | |
ATE508130T1 (de) | 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren | |
EA200401290A1 (ru) | НЕКОТОРЫЕ ПРОИЗВОДНЫЕ 1-(D-ЦИКЛОПРОПИЛГЛИЦИНИЛ)-4-(ПИПЕРИДИН-4-ИЛ)ПИПЕРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СЕРИНПРОТЕАЗЫ ФАКТОРА Xa | |
DE602004009313D1 (de) | Organosiliziumverbindungen und deren verwendung | |
ATE348803T1 (de) | Tryptase-inhibitoren | |
ATE364037T1 (de) | Tryptasehemmer |